Intelligence · Clinical Pipeline
Regeneron UK Pipeline
All ClinicalTrials.gov programs at Regeneron UK — phase, modality, and trial IDs.
- Programs
- 60
Quick answer
Regeneron UK has 60 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Intravitreal aflibercept injection 2.0mg
Regeneron UK Limited
Polypoidal Choroidal Vasculopathy
1 trial -
Pozelimab
Regeneron UK Limited
CHAPLE Disease
1 trial -
Praluent
Regeneron UK Limited
Heterozygous Familial Hypercholesterolemia
1 trial -
Praluent (Alirocumab)
Regeneron UK Limited
Hypercholesterolemia
1 trial -
Rescue Intravitreal Aflibercept Injection
Regeneron UK Limited
Neovascular Polypoidal Choroidal Vasculopathy
1 trial -
SAR231893
Regeneron UK Limited
Asthma
1 trial -
Sarilumab
Regeneron UK Limited
Rheumatoid Arthritis
8 trials -
Sarilumab
Regeneron UK Limited
Polymyalgia Rheumatica
1 trial -
aflibercept 2.0 mg
Regeneron UK Limited
Age Related Macular Degeneration
1 trial -
aflibercept 2.0 mg
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
dupilumab
Regeneron UK Limited
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
dupilumab
Regeneron UK Limited
Severe Atopic Dermatitis (AD)
1 trial
Frequently asked questions
How many pipeline programs does Regeneron UK have?
60 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs